RU2018114868A - COMPOSITION HYPERICIN FOR PHOTODYNAMIC DIAGNOSTICS - Google Patents

COMPOSITION HYPERICIN FOR PHOTODYNAMIC DIAGNOSTICS Download PDF

Info

Publication number
RU2018114868A
RU2018114868A RU2018114868A RU2018114868A RU2018114868A RU 2018114868 A RU2018114868 A RU 2018114868A RU 2018114868 A RU2018114868 A RU 2018114868A RU 2018114868 A RU2018114868 A RU 2018114868A RU 2018114868 A RU2018114868 A RU 2018114868A
Authority
RU
Russia
Prior art keywords
composition
hypericin
pvp
composition according
salt
Prior art date
Application number
RU2018114868A
Other languages
Russian (ru)
Other versions
RU2018114868A3 (en
Inventor
Кристина АБРАХАМСБЕРГ
Вернер ФРАНТЗИТС
Клаус ГЕРДЕС
Йожеф ГУНГЛЬ
Беате КЕЛЬЦ
Штефан ВЕЛЬЦИГ
Original Assignee
Санохемиа Фармацойтика Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санохемиа Фармацойтика Аг filed Critical Санохемиа Фармацойтика Аг
Publication of RU2018114868A3 publication Critical patent/RU2018114868A3/ru
Publication of RU2018114868A publication Critical patent/RU2018114868A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0071—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form solution, solute
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/36—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (10)

1. Композиция для фотодинамической диагностики, содержащая на полимерном комплексообразователе связанный или комплексованный гиперицин, отличающаяся тем, что гиперицин присутствует в виде соли.1. A composition for photodynamic diagnostics, containing bound or complexed hypericin on a polymer complexing agent, characterized in that the hypericin is present in the form of a salt. 2. Композиция по п.1, отличающаяся тем, что комплексообразователь представляет собой полиэтиленгликоль или поли-N-виниламид.2. The composition according to claim 1, characterized in that the complexing agent is a polyethylene glycol or poly-N-vinylamide. 3. Композиция по п.2, отличающаяся тем, что поли-N-виниламид представляет собой поливинилпирролидон (PVP) с различной степенью полимеризации и сшивания.3. The composition according to claim 2, characterized in that the poly-N-vinylamide is polyvinylpyrrolidone (PVP) with varying degrees of polymerization and crosslinking. 4. Композиция по п.3, отличающаяся тем, что поливинилпирролидон представляет собой PVP k17, PVP k25 или PVP k30.4. The composition according to claim 3, characterized in that the polyvinylpyrrolidone is PVP k17, PVP k25 or PVP k30. 5. Композиция по одному из пп. 1-4, отличающаяся тем, что соль гиперицина представляет собой соль щелочного металла, в частности, калиевую соль или, предпочтительно, натриевую соль.5. The composition according to one of paragraphs. 1-4, characterized in that the hypericin salt is an alkali metal salt, in particular a potassium salt or, preferably, a sodium salt. 6. Способ получения композиции по одному из пп. 1-5, отличающийся тем, что соль гиперицина связывается с полиэтиленгликолем или поли-N-виниламидом или образует комплекс с ним, предпочтительно с поливинилпирролидоном (PVP).6. A method of obtaining a composition according to one of paragraphs. 1-5, characterized in that the salt of hypericin binds to or forms a complex with polyethylene glycol or poly-N-vinylamide, preferably with polyvinylpyrrolidone (PVP). 7. Способ по п.6, отличающийся тем, что комплексообразование проводится в водном, при необходимости забуференном, растворе.7. The method according to claim 6, characterized in that the complexation is carried out in an aqueous, if necessary, buffered solution. 8. Способ по п. 6 или 7, отличающийся тем, что композиция приготавливается для внутривенного, внутриполостного, ингаляционного, орального, внутрибрюшинного и местного введения, в гидрофильных или гидрофобных носителях, предпочтительно в форме раствора, крема, геля, аэрозоля, эмульсий или в форме пластыря.8. The method according to p. 6 or 7, characterized in that the composition is prepared for intravenous, intracavitary, inhalation, oral, intraperitoneal and local administration, in hydrophilic or hydrophobic carriers, preferably in the form of a solution, cream, gel, aerosol, emulsions or patch form. 9. Способ по п. 7 или 8, отличающийся тем, что водный раствор заливается во флаконы для инъекций и подвергается лиофилизации.9. The method according to p. 7 or 8, characterized in that the aqueous solution is poured into injection bottles and lyophilized. 10. Применение композиции по одному из пп. 1-5, или полученной по одному из пп. 6-9 композиции, для приготовления фотосенсибилизатора, применимого при фотофизической или фотодинамической диагностике и для раннего выявления рака.10. The use of the composition according to one of paragraphs. 1-5, or obtained according to one of paragraphs. 6-9 of the composition, for the preparation of a photosensitizer, applicable for photophysical or photodynamic diagnosis and for early detection of cancer.
RU2018114868A 2015-09-28 2016-04-07 COMPOSITION HYPERICIN FOR PHOTODYNAMIC DIAGNOSTICS RU2018114868A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT6292015 2015-09-28
ATA629/2015 2015-09-28
PCT/AT2016/000034 WO2017054018A1 (en) 2015-09-28 2016-04-07 Formulation of hypericin for photodynamic diagnosis

Publications (2)

Publication Number Publication Date
RU2018114868A3 RU2018114868A3 (en) 2019-10-28
RU2018114868A true RU2018114868A (en) 2019-10-28

Family

ID=55854523

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018114868A RU2018114868A (en) 2015-09-28 2016-04-07 COMPOSITION HYPERICIN FOR PHOTODYNAMIC DIAGNOSTICS

Country Status (14)

Country Link
US (2) US9629932B2 (en)
EP (1) EP3237019B1 (en)
JP (1) JP6800232B2 (en)
KR (1) KR20180080210A (en)
CN (1) CN108289967A (en)
AU (1) AU2016330390B2 (en)
BR (1) BR112018006066A2 (en)
CA (1) CA3000419C (en)
DK (1) DK3237019T3 (en)
ES (1) ES2762902T3 (en)
MX (1) MX2018003802A (en)
PL (1) PL3237019T3 (en)
RU (1) RU2018114868A (en)
WO (1) WO2017054018A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108715693B (en) * 2018-06-29 2020-08-25 南方科技大学 Medium for protecting triplet excited state of photosensitizer by removing oxygen photochemically, and method and application thereof
EP3593815A1 (en) * 2018-07-13 2020-01-15 Planta Naturstoffe Vertriebsges.m.b.h. Hypericin-pvp complex with high hypericin content
CN114504551B (en) * 2020-11-16 2024-01-02 北京厚燊维康科技有限责任公司 Formulations useful for photodynamic therapy or diagnosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19756677A1 (en) 1997-12-19 1999-06-24 Krewel Meuselbach Gmbh Per-oral dry plant extract
DE19814014A1 (en) 1997-12-19 1999-09-30 Krewel Meuselbach Gmbh Medicinal plant dry extracts
EP1040825A1 (en) * 1999-03-11 2000-10-04 K.U. Leuven Research & Development Means for diagnosing bladder carcinoma
AT408835B8 (en) 2000-05-23 2002-07-25 Andreas Dipl Ing Dr Kubin PREPARATION OF HYPERICIN TIED TO POLYVINYLPYRROLIDONE (PVP) DIFFERENT GRADES OF POLYMERIZATION AND CROSSLINKING
CN102525937B (en) * 2012-01-21 2013-07-17 中国农业科学院兰州畜牧与兽药研究所 Preparation method for hypericin albumin nanometer particles
DE102014204138A1 (en) 2014-03-06 2015-09-24 Briu Gmbh Pharmaceutical formulation, process for the preparation of the pharmaceutical formulation and infusion solution and their use as a medical device and / or as a medicament
US10143751B2 (en) * 2015-09-28 2018-12-04 Sanochemia Pharmazeutika Ag Photodynamic therapy, formulation usable for this purpose, and method for the production and use thereof

Also Published As

Publication number Publication date
US20170087256A1 (en) 2017-03-30
US20170196976A1 (en) 2017-07-13
AU2016330390B2 (en) 2019-05-02
EP3237019B1 (en) 2019-10-09
AU2016330390A1 (en) 2018-05-10
BR112018006066A2 (en) 2018-10-09
DK3237019T3 (en) 2020-01-13
CN108289967A (en) 2018-07-17
CA3000419C (en) 2021-03-16
RU2018114868A3 (en) 2019-10-28
CA3000419A1 (en) 2017-04-06
US9629932B2 (en) 2017-04-25
ES2762902T3 (en) 2020-05-26
JP2018534349A (en) 2018-11-22
WO2017054018A1 (en) 2017-04-06
JP6800232B2 (en) 2020-12-16
US9775900B2 (en) 2017-10-03
MX2018003802A (en) 2019-06-24
KR20180080210A (en) 2018-07-11
EP3237019A1 (en) 2017-11-01
PL3237019T3 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
RU2018114868A (en) COMPOSITION HYPERICIN FOR PHOTODYNAMIC DIAGNOSTICS
HRP20191196T1 (en) Dermal injectable sterile composition
CY1120014T1 (en) PROTOTINIDE CONNECTION ANTIBODIES AND USE OF THESE IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR PARKINSON'S DISEASE, WITH LEWY BODIES AND ALPHABES
ES2658953T3 (en) Combinations and uses thereof
BR112018007683A2 (en) use of a first polysaccharide derivative and a second polysaccharide derivative, first and second polysaccharide derivatives, a combination of a first hyaluronic acid derivative (ah) and a second hyaluronic acid derivative (ah), multicylinder syringe system, kit for locally forming a cross-linked polysaccharide hydrogel, method for locally forming a cross-linked hydrogel
RU2017100445A (en) LYMPH TREATMENT
CY1124546T1 (en) LIQUID INHALATION PREPARATION CONTAINING RPL554
HRP20191523T1 (en) Spirocyclic isoxazoline parasiticidal combinations
SI3119794T1 (en) Formulation comprising a gemcitabine-prodrug
FI3227675T3 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
SI2709613T1 (en) Methods for treating hcv
WO2017100700A3 (en) Peptides for renal therapy
CY1109120T1 (en) PHARMACEUTICAL COMPOSITION OF VINFLUININ FOR INTENTIONAL ADMINISTRATION, METHOD OF PREPARATION AND USE
CY1122899T1 (en) AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN
RU2018114867A (en) COMPOSITION HYPERICIN FOR PHOTODYNAMIC THERAPY
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
JP2016534062A5 (en)
HRP20171514T1 (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors
RU2012129115A (en) METHOD FOR TREATING ACUTE POST-PERMANENT ENDOMETRITIS IN COWS
FI3058960T3 (en) Diagnostic agent for therapeutic effect on cancer
RU2018125571A (en) Method for modeling local limited peritonitis in rats
AR116019A1 (en) GUANIDINOBENZOYL DERIVATIVES AS ENTEROPEPTIDASE INHIBITORS
WO2015164581A8 (en) Pharmaceutical formulation of an anti-guanylyl cyclase c antibody conjugate comprising histidine or a salt thereof and polysorbate 20
RU2019113626A (en) An agent that increases cerebral blood flow
JP2019513151A5 (en)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200210